Click here to read the articles and download the PDF

Pharmaceutical Commerce - December 2024

Because of the potential for product shortages at pharmacies, the FDA has not only given industry more time for compliance—but time to catch up on boosting the supply chain’s interoperable efforts.

Did Industry Fumble the DSCSA Deadline?

A crash course on the bubble itself, including therapeutic areas most affected.

Going Inside the Gross-to-Net Bubble and Its Nuances

Addressing the bottlenecks in cell and gene therapy manufacturing through a well-designed artificial intelligence approach is essential to avoiding data siloes.

Why AI Advances in CGT Require Getting Data Right

Michael Christel is Group Managing Editor of Pharmaceutical Commerce, Pharmaceutical Executive, and Applied Clinical Trials. He can be reached at mchristel@mjhlifesciences.com.

Videos

In this Pharmaceutical Commerce video interview, Joerg Tritschler, a partner in Simon-Kucher’s life sciences division, discusses the hottest therapeutic settings for dealmaking activity at the moment—and one platform approach in particular poised to be at the center of future M&A and licensing pursuits.

Today’s Most Promising Therapeutic Areas for Dealmaking

Podcasts

Brandon Newman joins The Pharmaceutical Commerce Podcast to discuss the evolving role of PBMs, including the importance of drug price transparency. 

A Further Examination of Pharmacy Benefit Managers

In this Pharmaceutical Commerce video interview, Barry Heavey, Life Sciences Supply Chain Lead, Accenture, discusses the specific factors contributing to rising manufacturing costs. 

The Rising Tide of Biopharma Manufacturing Costs

Articles

The latest news for pharma industry insiders.

Pharma Pulse 3/29/24: Social Media Users Turn to Twitter for Guidance on Birth Control, Wider Availability of Oral Contraceptives & more

Five of the company’s vaccines are currently in Phase III. 

Various Vaccine Clinical Trials by Moderna Move on to Later Stages

In this Pharmaceutical Commerce video interview, Barry Heavey, Life Sciences Supply Chain Lead, Accenture, discusses what digital tools, beyond AI and ML, hold the most promise for reducing costs and increasing accessibility of treatments.

Reducing Costs and Increasing Accessibility of ADCs & Cell and Gene Therapies

Pharma Pulse 3/28/24: Do Mixed Results Impact Potential Real-World Effectiveness? FDA Issues Letters Over Unapproved, Misbranded OTC Analgesic Products & more

A study investigates how a New Mexico law can impact patients’ out-of-pocket costs surrounding mental health and substance use disorder medications. 

Does the Passing of a No Behavioral Health-Cost Sharing Law Have Any Bearing on Spending?

In this Pharmaceutical Commerce video interview, Barry Heavey, Life Sciences Supply Chain Lead, Accenture, discusses how companies can leverage digital tools like artificial intelligence and machine learning to optimize manufacturing processes and ensure efficient production.

Featured Content

Pharmaceutical Commerce - December 2024

Did Industry Fumble the DSCSA Deadline?

Going Inside the Gross-to-Net Bubble and Its Nuances

Why AI Advances in CGT Require Getting Data Right